肿瘤防治研究2023年第50卷第1期CancerResPrevTreat,2023,Vol.50,No.1·86·doi:10.3971/j.issn.1000-8578.2023.22.0120HER2阳性结直肠癌研究进展祁雅丽1，苟亚妮2，达丽隽1，李恩喜1，刘雅婷1，裴霞霞1，宋飞雪1ResearchProgressofHER2PositiveColorectalCancerQIYali1,GOUYani2,DALijun1,LIEnxi1,LIUYating1,PEIXiaxia1,SONGFeixue11.DepartmentofOncology,TheSecondHospitalofLanzhouUniversity,Lanzhou730000,China;2.DepartmentofGastroenterology,TheSecondHospitalofLanzhouUniversity,Lanzhou730000,ChinaCorrespondingAuthor:SONGFeixue,E-mail:sfx13639336037@163.comAbstract:Epidermalgrowthfactorreceptor2(HER2)isanoncogeneinvolvedintumourgenesisandprogression.Itisexpressedin7%ofpatientswithcolorectalcancer(CRC)andisassociatedwithdrugresistanceofepidermalgrowthfactorreceptormonoclonalantibodies.WiththeemergenceofthetherapeuticdilemmaofCRCandthesurvivalbenefitsoftargetingHER2forpatientswithbreastcancerandgastriccancer,thesignificanceofHER2inCRCandtheprognosticvalueofanti-HER2therapyhavebeenwidelyconcerned,clinicalresearchesonHER2-positiveCRChavebeencontinuouslycarriedout.Currently,thediagnosticcriteriaforHER2positiveCRChavegraduallybeenunified.HER2-targetingtherapiessuchasmonoclonalantibodies,tyrosinekinaseinhibitors,antibody-drugcouplingandHER2-relatedimmunotherapyaloneorincombinationhaveshowngoodefficacyandbroughtsignificantsurvivalbenefitsforHER2positiveCRC.ThispaperreviewstheresearchprogressofHER2inCRC.Keywords:Colorectalcancer;HER2/neu;Targettherapy;ImmunotherapyFunding:NaturalScienceFoundationofGansuProvince(No.21JR1RA121);UniversityInnovationFundProjectfromDepartmentofEducationofGansuProvince(No.2021B-043)Competinginterests:Theauthorsdeclarethattheyhavenocompetinginterests.摘要：表皮生长因子受体2（HER2）是肿瘤发生、发展过程中的癌基因，在7%的结直肠癌患者中表达，与表皮生长因子受体单克隆抗体的耐药相关。随着CRC治疗困境的出现，以及靶向HER2为乳腺癌、胃癌患者带来生存获益，HER2在CRC中的意义及抗HER2治疗的预后价值被广泛关注，围绕HER2阳性CRC的临床研究亦不断开展。目前，CRC中HER2阳性的诊断标准已逐渐统一，HE...
